Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanokine vs Eprex in Healthy Volunteers
NCT06919861Phase 1Not yet recruiting
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 1, randomised, open-label trial of Nanokine in anemia (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration up to 144 hours, Maximum Observed Concentration up to 144 hours and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Nanokine
03
Conditions
anemia
Beyond the preview
Go deeper on NCT06919861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919861.